A carregar...
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m(2) or greater...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3021887/ https://ncbi.nlm.nih.gov/pubmed/21253513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/957268 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|